Zimbabwe has rejected a significant American health deal worth $367m (£272m) spanning five years due to the United States' demand for confidential data.
This rejection came to light following a government memo dated December was leaked, revealing that President Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government spokesman later stated that the United States was demanding access to biological samples for scientific study and commercial purposes while was unwilling to share the benefits from any future vaccines.
"We must now begin the difficult and regrettable task of scaling back our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had donated over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged continued talks to reach a agreement acceptable to both sides so the country's critical HIV programme can proceed.
Broader Context
This development follows a comparable case in Kenya, where a court halted a similar deal with the US after concerns were filed about the security of citizens' medical information.
After resuming office last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had managed aid for the American government, but Trump claimed its spending was "wasteful" and his administration was seeking direct bilateral agreements to boost openness and accountability.
According to reports, 16 African countries have to date agreed to similar health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership might have yielded extraordinary advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently on antiretroviral therapy through US-supported programmes," Tremont commented.
However, government spokesperson Nick Mangwana said the proposed deal was "unfair".
"Our nation was requested to surrender its genetic material and health information for a long time, without any corresponding guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that might result from that shared data," Mangwana explained.
"Put simply, our country would provide the basic resources for medical research with no assurance that the end products would be available to our citizens should a future disease outbreak emerge."
National Interest and Global Health
Mangwana further said that the American exit from the global health body and its pursuit of one-on-one deals were disrupting frameworks already set up via the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to deal with potential global health emergencies.
"This framework is designed to ensure that when a nation contributes its information, the resulting advantages – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the funds to develop them."
The government's concerns over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We are open to further dialogue with our US partners on how future co-operation could be arranged in a way that respects the sovereignty and interests of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the official position, but urged that talks need to persist given that much of the country's HIV programmes relied on foreign aid.
"If specific concerns arise, including those involving data governance or agreement terms, these can often be addressed through detailed discussion and mutually agreed protections," it said.
The halted deal highlights the ongoing debate between accepting much-needed international aid and safeguarding a country's data in an increasingly data-driven world.